Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes

ACS Chemical Neuroscience - Tập 1 Số 6 - Trang 420-434 - 2010
Travis T. Wager1,2, Ramalakshmi Y. Chandrasekaran2, Xinjun Hou2, Matthew D. Troutman3, Patrick R. Verhoest2, Anabella Villalobos2, Yvonne Will4
1558 Eastern Point Road, Groton, CT, USA. [email protected]
2Neuroscience Medicinal Chemistry
3Department of Pharmacokinetics, Dynamics and Metabolism Screening CoE
4Compound Safety Prediction

Tóm tắt

Từ khóa


Tài liệu tham khảo

Kola I., 2004, Nat. Rev. Drug Discovery, 3, 711, 10.1038/nrd1470

O'Shea R., 2008, J. Med. Chem., 51, 2871, 10.1021/jm700967e

Leeson Paul D., 2004, J. Med. Chem., 47, 6338, 10.1021/jm049717d

Veber D. F., 2002, J. Med. Chem., 45, 2615, 10.1021/jm020017n

Proudfoot J. R., 2005, Bioorg. Med. Chem. Lett., 15, 1087, 10.1016/j.bmcl.2004.12.024

Leeson Paul D., 2007, Nat. Rev. Drug Discovery, 6, 881, 10.1038/nrd2445

Gleeson M. P., 2008, J. Med. Chem., 51, 817, 10.1021/jm701122q

Pajouhesh H., 2005, NeuroRX, 2, 541, 10.1602/neurorx.2.4.541

Lipinski C. A., 2005, Annu. Rep. Comput. Chem., 1, 155, 10.1016/S1574-1400(05)01011-X

Hitchcock S. A., 2006, J. Med. Chem., 49, 7559, 10.1021/jm060642i

Leeson P. D., 2004, Drug Discovery Today: Technol., 1, 189, 10.1016/j.ddtec.2004.11.005

Abraham M. H., 2002, Drug Discovery Today, 7, 1056, 10.1016/S1359-6446(02)02478-9

Lipinski C. A., 1997, Adv. Drug Delivery Rev., 23, 3, 10.1016/S0169-409X(96)00423-1

Feng B., 2008, Drug Metab. Dispos., 36, 268, 10.1124/dmd.107.017434

Whalen K., 2006, Rapid Commun. Mass Spectrom., 20, 1497, 10.1002/rcm.2469

Abad-Zapatero C., 2007, Expert Opin. Drug Discovery, 2, 469, 10.1517/17460441.2.4.469

Keserue G. M., 2009, Nat. Rev. Drug Discovery, 8, 203, 10.1038/nrd2796

Hughes J. D., 2008, Bioorg. Med. Chem. Lett., 18, 4872, 10.1016/j.bmcl.2008.07.071

Ertl P., 2000, J. Med. Chem., 43, 3714, 10.1021/jm000942e

Waring M. J., 2009, Bioorg. Med. Chem. Lett., 19, 2844, 10.1016/j.bmcl.2009.03.109

Ploemen J.-P. H. T. M., 2004, Exp. Toxicol. Pathol., 55, 347

Gao H., 2008, Drug Metab. Dispos., 36, 2130, 10.1124/dmd.107.020131

Hosea N. A., 2009, J. Clin. Pharmacol., 49, 513, 10.1177/0091270009333209

Van de Waterbeemd H., 2001, J. Comput.-Aided Mol. Des.n, 15, 273, 10.1023/A:1008192010023

Kaye C. M., 1989, Acta Psychiatr. Scand., Suppl., 350, 60, 10.1111/j.1600-0447.1989.tb07176.x

Leach A. R., 2006, Mol. BioSyst., 2, 429, 10.1039/b610069b

Houck K. A., 2008, Toxicol. Appl. Pharmacol., 227, 163, 10.1016/j.taap.2007.10.022

Miller V. P., 2000, Ann. N. Y. Acad. Sci., 919, 26, 10.1111/j.1749-6632.2000.tb06864.x

Fermini B., 2003, Nat. Rev. Drug Discovery, 2, 439, 10.1038/nrd1108

Deacon M., 2007, J. Pharmacol. Toxicol. Methods, 55, 238, 10.1016/j.vascn.2006.09.003

Leeson P. D., 2007, Nat. Rev. Drug Discovery, 6, 881, 10.1038/nrd2445

Walum E., 2005, Toxicol. Appl. Pharmacol., 207, S393, 10.1016/j.taap.2005.01.056

JMP. ( (1989−2007) SAS JMP 7,SAS Institute, Inc.Cary, NC.

Spotfire. (1996−2007) Spotfire Decision Site 9,TIBCO Softrware Inc.,Somerville, MA.

Hop C. E. C. A., 2008, Curr. Drug Metab., 9, 847, 10.2174/138920008786485092